Navigation Links
Ruedi Waeger Receives the 2010 Robert W. Reilly Leadership Award from Plasma Protein Therapeutics Association
Date:6/25/2010

RESEARCH TRIANGLE PARK, N.C., June 25 /PRNewswire-FirstCall/ -- Ruedi Waeger, Ph.D., former president and CEO of Aventis Behring LLC and a member of the Talecris Board of Directors, was honored with the Robert W. Reilly Leadership award June 15 at the 2010 Plasma Protein Forum in Reston, VA.

The award is sponsored by the Plasma Protein Therapeutics Association (PPTA) and recognizes individuals who exemplify the leadership qualities of Robert Reilly, former leader of the PPTA. Reilly's efforts improved the quality of plasma products in the U.S. and enhanced the reputation of the plasma therapeutics industry worldwide.

Waeger was bestowed the award because of his significant contributions toward improving patient access to therapies, ensuring the highest quality and safety of plasma-derived products, and striving to achieve worldwide regulatory standardization of protein therapies.

"Ruedi's accomplishments throughout his 30-year career have contributed immensely to the field of protein therapeutics, and we are pleased that his accomplishments have been recognized by the industry," said Lawrence D. Stern, chairman and CEO of Talecris. "Ruedi's breadth of knowledge and experience continue to be tremendously valuable to Talecris, and we congratulate him on having received this honor from the PPTA."

Waeger has served on the Talecris Board since April 2005 and currently chairs the compliance committee. He also serves on the nominating and governance committees.  Waeger has more than 30 years of experience in the global pharmaceutical and therapeutic protein industries. Prior to joining the Talecris board, Waeger served as President and CEO of the plasma therapeutics company Aventis Behering LLC. Prior to that, he served as President and CEO of ZLB Central Laboratories and the Blood Transfusion Service of the Swiss Red Cross. Waeger earned a Ph.D. in biochemistry from the Swiss Federal Institute of Technology.

About the Robert W. Reilly Leadership Award

Robert Reilly was a leader in the plasma therapeutics industry association from 1992 to 1998. He created the first educational programs and industry symposia to confront the challenges facing the plasma industry worldwide. He also contributed significantly to the development of voluntary industry standards for quality plasma programs throughout the U.S., and his work helped open communications and build relationships with regulatory authorities and consumer groups.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit: www.talecris.com


'/>"/>
SOURCE Talecris Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
2. Corgenix Receives Additional European Patent, Announces Publication of Important Clinical Study on AtherOx(R) Technology
3. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
4. Nile Therapeutics Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule
5. Alexandria Real Estate Equities, Inc. Receives Final Approval From City of Cambridge to Develop Its East Cambridge State-of-the-Art Life Science Community
6. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
7. Fenwal Scientist Receives Research Award for Work on Photopheresis Therapy
8. China Sky One Medical Receives GMP Re-Certification
9. SyntheMed Receives CE Mark Approval for REPEL-GYN™
10. Repligen Receives Orphan Drug Designation from the FDA for RG2833 for Friedreichs Ataxia
11. Biomedical Structures Receives Growth Capital from Ampersand Ventures to Fund Ongoing Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour Research & ... Q1 wave of its quarterly wearables survey. A particular ... a program where they would receive discounts for sharing ... "We were surprised to see that so many ... CEO of Troubadour Research, "primarily because there are segments ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... their customers enhanced security to access and transact ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):